title: Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
abstract: Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the field over the past decade, including the frequent use of tandem aHSCT in MM, the advent of novel therapies for the treatment of MM and lymphoma, and the addition of new stem cell mobilization techniques, have led to the need to reassess current stem cell mobilization strategies. Mobilization failures with traditional strategies are common and result in delays in treatment and increased cost and resource utilization. Recently, plerixafor-containing strategies have been shown to significantly reduce mobilization failure rates, but the ideal method to maximize stem cell yields and minimize costs associated with collection has not yet been determined. A panel of experts convened to discuss the currently available data on autologous hematopoietic stem cell mobilization and transplantation and to devise guidelines to optimize mobilization strategies. Herein is a summary of their discussion and consensus.
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: GiraltS@mskcc.org.
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.affiliation: Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
authors.forename: Luciano
authors.initials: L
authors.lastname: Costa
authors.affiliation: Cancer Transplant Institute, Virginia G Piper Cancer Center, Scottsdale, Arizona.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Schriber
authors.affiliation: Washington University School of Medicine in St. Louis, St. Louis, Missouri.
authors.forename: John
authors.initials: J
authors.lastname: Dipersio
authors.affiliation: Oregon Health and Science University, Portland, Oregon.
authors.forename: Richard
authors.initials: R
authors.lastname: Maziarz
authors.affiliation: Adult Bone Marrow Transplant, Virginia Commonwealth University, Richmond, Virginia.
authors.forename: John
authors.initials: J
authors.lastname: McCarty
authors.affiliation: Adult Bone Marrow Transplant, Texas Transplant Institute, San Antonio, Texas.
authors.forename: Paul
authors.initials: P
authors.lastname: Shaughnessy
authors.affiliation: Yale University Medical School, New Haven, Connecticut.
authors.forename: Edward
authors.initials: E
authors.lastname: Snyder
authors.affiliation: Fred Hutchinson Cancer Research Institute, Seattle, Washington.
authors.forename: William
authors.initials: W
authors.lastname: Bensinger
authors.affiliation: Levine Cancer Institute I, Carolinas HealthCare System, Charlotte, North Carolina.
authors.forename: Edward
authors.initials: E
authors.lastname: Copelan
authors.affiliation: MD Anderson Cancer Center, Houston, Texas.
authors.forename: Chitra
authors.initials: C
authors.lastname: Hosing
authors.affiliation: Stanford School of Medicine, Stanford, California.
authors.forename: Robert
authors.initials: R
authors.lastname: Negrin
authors.affiliation: Intermountain Blood and Marrow Transplant Program, Intermountain Healthcare, Salt Lake City, Utah.
authors.forename: Finn Bo
authors.initials: FB
authors.lastname: Petersen
authors.affiliation: Section of Hematology/Oncology, University of Illinois at Chicago Cancer Center, Chicago, Illinois.
authors.forename: Damiano
authors.initials: D
authors.lastname: Rondelli
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
authors.forename: Robert
authors.initials: R
authors.lastname: Soiffer
authors.affiliation: University of Florida, Gainesville, Florida.
authors.forename: Helen
authors.initials: H
authors.lastname: Leather
authors.affiliation: Adult Bone Marrow Transplant, University of Florida, Gainesville, Florida.
authors.forename: Amy
authors.initials: A
authors.lastname: Pazzalia
authors.affiliation: Department of Internal Medicine/Hematology/Oncology, Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
authors.forename: Steven
authors.initials: S
authors.lastname: Devine
mesh_terms: D001596:Benzylamines; D000080027:Cyclams; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods* / Q000592:standards; D018380:Hematopoietic Stem Cell Transplantation; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D009101:Multiple Myeloma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000627:therapeutic use; D016019:Survival Analysis; D014182:Transplantation, Autologous
chemical_list: D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim; C088327:plerixafor
keywords: Chemomobilization; Growth factors; Mobilization; Mobilization failure; Optimal collection; Plerixafor